Top ten stories in the pharmaceutical industry this week
pharmafile | August 5, 2016 | News story | Medical Communications, Research and Development | Actavis, Bioelectronics, CDF, Celgne, EMA, GSK, GlaxoSmithKline, Innovate UK, Medivation, NICE, Novartis, Roche, Sanofi, Teva, appointments, apremilast, biog, breast cancer, brexit, google, pharmaceutical industry, rheumatoid arthritis, sarilumab, top ten
It’s Friday, and we’ve seen some big developments in the industry’s headlines throughout the week, from news of Glaxo-Smith-Kilne’s new bioelectronics partnership with Google to the completion of Teva’s long-delayed acquisition of Actavis Generics. But far and away the most read story this week is Vincenzo Salvatore’s feature outlining his predictions on the impact Brexit will have on the pharma industry.
1. The impact of Brexit on the pharmaceutical industry: some preliminary considerations
The outcome of the popular vote cast on 23 June 2016 will be remembered as the start of a new era in the history of UK-EU relations
2. GSK and Alphabet to create bioelectronics medicines in £540 million partnership
The companies have come together to form Galvani Bioelectronics, which will be headquartered in the UK
3. Teva completes $40 billion acquisition of Actavis Generics
The pharmaceutical firm reports it is “stronger than ever” after assimilating Allergan’s subsidiary
4. American pharmacy adds 35 products to list of excluded drugs
Medivation’s prostate cancer drug Xtandi and Sanofi’s insulin Lantus are among those added to the list
5. NICE recommends Celgene’s apremilast for NHS use
The decision follows the organisation’s rejection of the drug last year
6. Innovate UK appoints first director of Health and Life Sciences
Ian Campbell has been named by the company UK as its first director in the newly created position
7. Breakthrough therapy designation for Novartis in advanced breast cancer treatment
LEE011 (ribociclib) is under investigation in HR+/HER2- advanced breast cancer
8. EMA accepts MMA for rheumatoid arthritis treatment Sarilumab
Sanofi and Regeneron announce acceptance of marketing authorisation application for new drug
9. Roche urges reform of Cancer Drugs Fund as NICE takes control
UK general manager Richard Erwin has called for government action on a drug appraisal system that “is broken at both ends”
10. Takeover rumours send Biogen’s stock soaring
Allergan and MSD are said to be considering a big for the Massachusetts biotech, whose current market cap is $75.3 billion
Matt Fellows
Related Content
Roche’s Alecensa approved by FDA as lung cancer treatment
Roche has announced that the US Food and Drug Administration (FDA) has approved Alecensa (alectinib) …
GSK shares results from phase 3 trial for gonorrhoea treatment
GSK has announced positive results from its phase 3 EAGLE-1 trial for gepotidacin, a potential …
Novartis shares new data about Fabhalta for IgAN treatment
Novartis has announced new results from a pre-specified interim analysis of its phase 3 APPLAUSE-IgAN …
